Activities of Biapenem against *Mycobacterium tuberculosis* in Macrophages and Mice

GUO Zhen Yong, ZHAO Wei Jie, ZHENG Mei Qin, LIU Shuo, YAN Chen Xia, LI Peng, and XU Shao Fa

*Beijing Chest Hospital affiliated with the Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Institute, Beijing 100049, China*

**Abstract**

**Objective** To assess the activities of biapenem against multidrug-resistant and extensively drug-resistant *Mycobacterium tuberculosis*.

**Methods** Biapenem/clavulanate (BP/CL) was evaluated for *in vitro* activity against *Mycobacterium tuberculosis* (*Mtb*) multidrug-resistant (MDR) isolates, extensively drug-resistant (XDR) isolates, and the H37RV strain. BP/CL activity against the H37Rv strain was assessed in liquid cultures, in macrophages, and in mice.

**Results** BP/CL exhibited activity against MDR and XDR *Mtb* isolates in liquid cultures. BP/CL treatment significantly reduced the number of colony forming units (CFU) of *Mtb* within macrophages compared with control untreated infected macrophages. Notably, BP/CL synergized in pairwise combinations with protonamide, aminosalicylate, and capreomycin to achieve a fractional inhibitory concentration for each pairing of 0.375 *in vitro*. In a mouse tuberculosis infection model, the efficacy of a cocktail of levofloxacin + pyrazinamide + protonamide + aminosalicylate against *Mtb* increased when the cocktail was combined with BP/CL, achieving efficacy similar to that of the positive control treatment (isoniazid + rifampin + pyrazinamide) after 2 months of treatment.

**Conclusion** BP/CL may provide a new option to clinically treat MDR tuberculosis.

**Key words:** Biapenem; Clavulanate; Multidrug resistant; Extensive drug-resistant; *Mycobacterium tuberculosis*; Activity; Macrophage; Synergy

**INTRODUCTION**

In 2017, the WHO reported that the number of new tuberculosis (TB) cases reached 10.0 million, with 1.6 million deaths. Among the new cases, it was estimated that 350,000 cases were multidrug-resistant tuberculosis (MDR-TB) cases, defined by resistance to two main anti-TB drugs, isoniazid and rifampin. Treatment success remains low, at 55% globally[1]. Due to improper use of second-line anti-TB drugs, extensive drug-resistant tuberculosis (XDR-TB) cases caused by MDR-TB bacilli that are also resistant to fluoroquinolones and either amikacin, kanamycin, or capreomycin have increased significantly. Among patients with MDR-TB, 9.7% are XDR-TB cases with mortality rates of 65% -100% due to the lack of effective treatment regimens[1]. The emergence of MDR-TB, particularly...
in human immunodeficiency virus-infected patients, highlights the need for new compounds to treat these infections.

As *Mycobacterium tuberculosis* (*Mtb*) produces β-lactamase, an enzyme that hydrolyzes β-lactam antibiotics, such drugs are not clinically used to treat TB. However, in recent years the β-lactam antibiotic meropenem, a carbapenem derivative, has been reported to control MDR-TB successfully when used in combination with clavulanate (CL)\(^{[2]}\). Several mechanisms account for the effectiveness of this drug combination *in vitro*\(^{[3-6]}\). Furthermore, meropenem is active against XDR-TB and is well tolerated by patients\(^{[7,8]}\). Biapenem (BP), a newer carbapenem, is also active against *Mtb in vitro* when combined with CL\(^{[9,10]}\). Here we evaluated the *in vitro* activity of BP/CL against MDR-TB and *Mtb* (H37Rv) in macrophages. We then tested BP/CL in combination with other second-line anti-TB drugs for activity against MDR-TB both *in vitro* and *in vivo* in mice. The results suggest that BP/CL is a potent drug combination against MDR-TB.

**METHODS**

**Bacterial Strains and Culture Conditions**

*Mtb* H37Rv (ATCC 27294) and the clinical isolates (17 MDR-TB and 4 XDR-TB, all from the National Clinical Laboratory on Tuberculosis) were grown at 37 °C in 5% ambient CO\(_2\) for 14 days in Middlebrook 7H9 broth (Becton Dickinson, Sparks, MD, USA) supplemented with 0.2% (v/v) glycerol (Sigma, St. Louis, MO, USA), 10% (v/v) oleic acid–albumin–dextrose-catalase (OADC; Becton Dickinson) and 0.05% (v/v) Tween 80 (Sigma). The bacteria were washed, suspended in phosphate-buffered saline, and passed through a filter (8-µm pore size) to eliminate clumps. The filtrates were aliquoted and stored at -80 °C for use within 30 days.

**Drugs and Chemicals**

Chemicals were purchased in pure form from various manufacturers: levofloxacin (Lfx) from Shuanghe Pharmaceutical Co., Ltd. (Beijing, China); clofazimine (CFZ) from Nanjing Liye Pharmaceutical Co., Ltd. (Nanjing, Jiangsu, China); aminosalicylate (PAS), protonamide (Pto) and capreomycin (CPM) from Shanghai Xinyi Pharmaceutical Co., Ltd. (Shanghai, China); rifampin (RIF), pyrazinamide (PZA) and isoniazid (INH) from Sigma; linezolid (LZD) from Pfizer (Andover, MA, USA); BP from Zhengda Tianqing Pharmaceutical Co., Ltd. (Jiangsu, China); and CL from Aladdin Industrial Corp. (Calhoun, GA, USA).

**Determination of Minimum Inhibitory Concentration (MIC) and Synergy**

Initial stock solutions of Lfx, CPM, PAS, BP/CL, Pto, and CFZ were constituted in dimethyl sulfoxide (DMSO) at concentrations of 10 or 20 g/L. Dilutions were made from the stock solutions in 7H9 broth. To avoid solvent effects, the highest concentration of DMSO was 0.5%. BP and CL were dissolved just before use. The MICs of the antimicrobial agents were determined against *H37Rv* strain using a microplate Alamar Blue assay\(^{[11]}\) with serial two-fold dilutions of the drugs. The MICs of the combinations of BP/CL and other second-line anti-TB agents were determined in 96-well microtiter plates using the dynamic checkerboard method\(^{[12]}\). Initial concentrations of Lfx, CPM, PAS, CFZ, LZD, and Pto were 1, 4, 1, 0.48, 1, and 2 µg/mL, respectively, and the final concentrations of the drugs (two-fold dilutions) ranged from 1/8× to 1× of the MIC of each drug.

The data were interpreted by calculating the fractional inhibitory concentration (FIC) as following formula: FIC = (A/MIC\(_A\)) + (B/MIC\(_B\)), where A and B represent the MICs of each drug combination, and MIC\(_A\) and MIC\(_B\) represent the MICs of each drug alone. The FIC results reflect synergy for FIC < 0.5\(^{[13,14]}\).

**Activity of BP/CL in Macrophages**\(^{[15]}\)

After the cultured macrophage cell line J774.A.1 was suspended in antibiotic-free Dulbecco’s Modified Eagle Medium (DMEM and 10% fetal bovine serum), the cell suspension was added to 24-well tissue culture plates at a cell density of 5 × 10\(^5\) CFU/mL. The plates were incubated at 37 °C for 12 h in 5% CO\(_2\). The macrophages were infected with a 100-µL bacterial suspension containing 5 × 10\(^6\) CFU/mL *Mtb* H37Rv and incubated for 4 h. The cells were washed with prewarmed serum-free DMEM to remove extracellular bacteria from the adherent cells. Next, 1 mL of DMEM with or without drugs was added, and the plates were incubated in 5% CO\(_2\) as described above for 2 days. Wells containing cells without added drugs served as negative controls. The BP concentrations were 40 and 20 µg/mL, and the concentrations of CL and INH were 2.5 and 2 µg/mL, respectively. Due to the instability of BP and CL in medium, spent medium was replaced with new
medium containing freshly constituted BP/CL twice each day. Two days after infection, each macrophage monolayer was lysed with 0.2 mL of 7H9 medium containing 0.1% SDS. Next, the lysates were serially diluted and dilutions were inoculated onto OADC-enriched 7H11 agar medium for enumeration of CFU.

**Aerosol Infection**

Male 6-week-old BALB/c mice (Beijing Vital River Laboratory Animal Technology Co., Ltd., Beijing, China) were infected with the H37Rv strain using a Glas-col inhalation exposure system (Glas-col Inc., Terre Haute, IN, USA) and a fresh log-phase broth culture to implant 3 log_{10} CFU into the lungs of each mouse. Five mice were sacrificed the following day to determine the number of CFUs implanted in the lungs. All animal procedures were approved by the Animal Care and Use Committee of the Beijing Tuberculosis and Thoracic Tumor Institute (No. 2017009).

**Chemotherapy**

After infection, the mice were randomly assigned to one of the nine treatment groups described in Table 1. The first group was a negative control group that included infected mice receiving no treatment. The last group was a positive control group of mice treated with the standard RIF-INH-PZA (RHZ) TB-treatment regimen. Mice in the remaining groups were treated with additional antibiotics. The treatment began 15 days after infection (on day 0) to attain a high initial bacterial burden within the lungs of mice. Treatment was administered 5 days per week thereafter. For consistency, 4 weeks were considered equivalent to 1 month of treatment. Drugs were administered in the doses shown in Table 2. Based on the areas under the concentration (AUC)-time curves, these doses were chosen due to equipotency with the usual doses administered to humans and were similar to doses used in previous studies. All regimens were administered for 2 months. BP and CL were given by subcutaneous injection twice each day, 5 days per week. The remaining drugs were administered by gavage.

**Assessment of Infection and Treatment**

To provide baseline values, a group of five infected but untreated mice were euthanized per day on days 1 and 15 after infection (days designated: -14 and 0 in relation to initiation of treatment). The treated mice were euthanized after 1 and 2 months of treatment to determine lung CFU

<table>
<thead>
<tr>
<th>Table 1. Experimental Design Used in This Study</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Group</strong></td>
</tr>
<tr>
<td>A</td>
</tr>
<tr>
<td>B</td>
</tr>
<tr>
<td>C</td>
</tr>
<tr>
<td>D</td>
</tr>
<tr>
<td>E</td>
</tr>
<tr>
<td>F</td>
</tr>
<tr>
<td>G</td>
</tr>
<tr>
<td>H</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>Total No. of mice</td>
</tr>
</tbody>
</table>

**Note.** aDrugs were administered 5 days per week at the following doses: BP (100), CL (100), PAS (750), Pto (100), Lfx (200), RFP (10), INH (25), and PZA (150). bMice were sacrificed at the following times: 1 day after infection (D-14); 15 days after infection [day 0 (D0)]; 1, 2 months after treatment (M1, M2, respectively).
counts. The numbers of CFUs within the lungs were determined on days -14 and 0 and after 1 month of treatment by plating four serial 10-fold dilutions of homogenized suspensions onto OADC-enriched 7H11 agar medium. After 2 months of treatment, the entire suspension prepared from each individual organ, predicted to contain few bacilli, was plated without dilution onto OADC-enriched 7H11 agar medium. The results for the various cultures were recorded after a 4-week incubation at 37 °C. The bactericidal effect of each treatment was defined as a significant decrease in the mean number of CFUs compared to the corresponding infected untreated control tissue CFU values.

**Statistical Analysis**

CFU counts were converted to log10 values before analysis, and each was expressed as CFU log10 ± standard error. Experimental group means were compared to means of the untreated infected group by two-way analysis of variance using Fisher’s exact test. Differences were considered significant at a P-value < 0.05. The data analysis was performed using the Statistical Package for the Social Sciences software (SPSS 17.0; IBM, Armonk, NY, USA).

**RESULTS**

**Determination of MICs of BP/CL against Various Mtb Isolates**

The MICs of BP/CL against H37Rv, the 17 MDR, and the four XDR isolates were determined according to a standard two-fold agar dilution method under defined conditions as described above. The MIC of BP/CL against H37Rv was 2 µg/mL and ranged between 0.5 and 8 µg/mL for the 17 MDR strains and between 1 and 4 µg/mL for the four XDR strains (Figure 1). No differences were observed between the MICs of BP/CL when compared with H37Rv, MDR-, or XDR-TB (P > 0.05).

The dynamic checkerboard method was used to evaluate the effects of BP/CL combined with either CLF, PAS, Pto, LZD, Lfx, or CPM on MTb CFUs (Table 3). The FIC of BP/CL and pairwise combinations with either PAS, Pto, or CPM was 0.375, indicating that synergy existed between each pair of drugs tested. Combinations of BP/CL with each of the other three drugs only exhibited additive effects.

![Figure 1. Minimum inhibitory concentrations (MICs) of biapenem/clavulanate (BP/CL) against extensive drug-resistant tuberculosis (XDR-TB), multidrug-resistant tuberculosis (MDR-TB), and the H37Rv strain in vitro.](image)

**Table 3. Fractional Inhibitory Concentration (FICs) of Biapenem/Clavulanate (BP/CL) Combinations with Other Second-line Anti-tuberculosis (TB) Drugs in vitro**

<table>
<thead>
<tr>
<th>Agents</th>
<th>BP/CL</th>
<th>LZD</th>
<th>BP/CL</th>
<th>Pto</th>
<th>BP/CL</th>
<th>Lfx</th>
<th>BP/CL</th>
<th>PAS</th>
<th>BP/CL</th>
<th>CPM</th>
<th>BP/CL</th>
<th>CLF</th>
</tr>
</thead>
<tbody>
<tr>
<td>MICalone</td>
<td>2</td>
<td>0.5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0.5</td>
<td>2</td>
<td>0.25</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0.24</td>
</tr>
<tr>
<td>MICcombination</td>
<td>1</td>
<td>0.0625</td>
<td>0.25</td>
<td>0.5</td>
<td>1</td>
<td>0.0625</td>
<td>0.25</td>
<td>0.0625</td>
<td>0.5</td>
<td>0.25</td>
<td>1</td>
<td>0.06</td>
</tr>
<tr>
<td>FIC</td>
<td>0.625</td>
<td>0.375</td>
<td>0.625</td>
<td>0.375</td>
<td>0.375</td>
<td>0.375</td>
<td>0.375</td>
<td>0.75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note.** "MICalone: MIC of agent alone against H37Rv; "MICcombination: MIC of agents combined against H37Rv; "FIC < 0.5 means these two drugs were synergistic."
Activity of BP/CL against Mtb H37Rv in Macrophages

The activity of BP/CL by day 2 of treatment against H37Rv within macrophages (infected at a MOI = 1) is presented in Figure 2. BP/CL (40 and 20 µg/mL) demonstrated 1.3- and 0.9-log reductions in bacterial numbers, respectively, compared to results for untreated infected control macrophages. INH decreased CFU by 2.1-log and BP/CL40, BP/CL20, and INH were each active against H37Rv within macrophages compared to infected untreated macrophage controls (infected with H37Rv). Although a significant difference was observed between BP/CL40 and INH activities ($P = 0.03$), no difference was observed between the BP/CL40 and BP/CL20 treatments.

Activity of BP/CL Combined with Other Agents in Vivo

On the day after the aerosol infection, the lung CFU count (mean ± standard error) was $3.24 ± 0.06 \log_{10}$ with a mean lung CFU count at the initiation of treatment (15 days after infection) of $4.98 ± 0.10 \log_{10}$.

To evaluate the synergy of BP/CL with PAS and Pto in vivo, we determined the CFUs in lungs of mice after treatment with BP/CL, PAS, Pto, BP/CL + PAS; and BP/CL + Pto. After 2 months, the CFU result of the BP/CL + PAS group was no different from the results of the BP/CL, PAS and BP/CL + Pto groups. Moreover, no drug interactions were observed for any of the drug combinations administered in vivo (Figure 3A and 3B).

At the same time, the activities of three regimens (RHZ; Lfx + PZA + Pto + PAS; and Lfx + PZA + Pto + PAS + BP/CL) against TB were determined in mice. After 2 months of treatment, the CFUs in the lungs of all groups declined significantly compared with control untreated infected lungs (Figure 3C). Lfx + PZA + Pto + PAS reduced the number of bacilli in the lungs by $4.06 \log_{10}$. When BP/CL was combined with the Lfx + PZA + Pto + PAS regimen, CFUs
significantly decreased further by 4.51 log_{10} (P = 0.0049). However, no difference was observed between the Lfx + PZA + Pto + PAS + BP/CL and RHZ groups (P = 0.2125).

**DISCUSSION**

Most drugs to treat MDR-TB exhibit low efficacy and are accompanied by side effects. For example, LZD exhibits hematologic toxicity\[^{18}\], while cycloserine exhibits central nervous system toxicity\[^{19}\]. Therefore, carbapenem drugs, with high efficacy and low toxicity, are attracting strong interest as potential therapies against drug-resistant *Mtb*. Based on our research, BP could kill *Mtb* in vitro with a MIC of 2-4 µg/mL, regardless of whether it was H37Rv, MDR-TB, or XDR-TB.

As *Mtb* is a typical intracellular parasite that can survive and reproduce in macrophages, intracellular *Mtb* can only be killed by drugs that enter macrophages. Therefore, we investigated the antibacterial activity of BP against *Mtb* within macrophages and found that BP/CL exhibited a killing effect at concentrations of 20 and 40 µg/mL. The CFU counts decreased by 0.9-log and 1.3-log after 2 days of BL/CL administration, respectively, which was significantly different compared to the infected untreated control group. However, no significant difference was found in bactericidal activity between the 20 and 40 µg/mL groups. The dosing regimen for intravenous BP is usually 300-600 mg Q12H in clinical practice and the serum Cmax value is between 14.7-15.6 µg/mL and 31.5-35.7 µg/mL\[^{20}\]. According to our study, no difference was found in the bactericidal killing function between these two concentrations, therefore the 600 mg BP dosing regimen of Q12H is feasible.

The WHO has recommended a MDR-TB regimen that consists of five to six drugs. If there is a synergistic effect among the drugs, this would increase the antibacterial activity of individual drugs and reduce side effects\[^{21}\]. Research has shown that meropenem combined with CL can decrease the MIC of meropenem against *Mtb*, ultimately improving the antibacterial activity of meropenem. Another study revealed a synergistic effect between BP and RIF\[^{10}\] and our results here show synergy (FIC = 0.375) between BP/CL and the second-line anti-TB drugs PAS, CPM, and Pto. Such synergistic effects may be due to the destruction of the *Mtb* cell wall by BP/CL, leading to increased drug entry into the bacteria.

The *in vitro* antibacterial activities or synergistic effects of drugs do not always guarantee the same effects *in vivo*. Therefore, we investigated the interactions between BP/CL and either PAS or Pto in mice. The results showed that although there were synergistic effects *in vitro* between BP/CL and PAS or between BP/CL and Pto, neither pairwise combination exhibited synergy in reducing lung tissue CFU counts *in vivo*. This discrepancy may be related to the poor tissue-penetrating ability of PAS\[^{15}\], resulting in far lower amounts entering tissues than effective tissue concentrations needed for achieving synergy with BP/CL. Nevertheless, the reason behind the lack of synergy *in vivo* between BP/CL and Pto remains unclear.

In addition, we investigated the therapeutic effect of Lfx + PZA + Pto + PAS, an anti-*Mtb* chemotherapeutic regimen commonly used clinically, to investigate its therapeutic effect against TB in mice when combined with BP/CL. The results showed that adding BP/CL significantly reduced the CFU counts in mouse lung tissue, achieving activity similar to that observed for the classical RHZ therapeutic scheme. However, neither of these therapies eliminated the bacteria in mouse lungs after 2 months of treatment.

Several factors might have affected drug efficacy *in vivo*. First, because the antibacterial activity of BP is time-dependent, BP must be injected subcutaneously into mice twice a day, causing greater stress and a poor mental state in the animals. Second, although BP does not require additional administration of cilastatin to inhibit renal dehydropeptidase-I, BP is pharmacokinetically reduced via hydrolysis faster in mice than in humans due to higher kidney dehydrogenation enzyme activity in mice. This appears to also be true in rabbits, as England et al. reported significantly reduced C\(_{max}\), t\(_{1/2}\) and AUC-time curve of meropenem in rabbits\[^{22}\]. Therefore, underestimating the antibacterial activity of BP is a possible when using a murine TB model. Third, BP and CL are easily hydrolyzed, even if freshly prepared just prior to administration, resulting in reduced efficacy.

Although the experiment demonstrated that BP/CL had anti-TB activity, this study had several limitations. First, the mice only received the treatments for 2 months. As long-term treatment efficacy remains unclear, future studies on the long-term treatment effects will be conducted by our group. Moreover, although BP/CL showed an anti-tuberculosis effect *in vivo*, the difference in
effect between human and mouse kidney dehydrogenase on drug efficacy was not addressed and may have impacted our drug efficacy estimates. Another limitation of our study was that only the standard H37Rv MTB strain was used to access in vivo activity of BP/CL against MTB rather than a drug-resistant MTB strain. A further in vivo study with drug-resistant MTB strains will extend our knowledge of the in vivo anti-TB efficacy of this combination.

CONCLUSION

Our study demonstrated that BP/CL has antibacterial activity against Mtb, and thus may serve as a new clinical treatment option for treating MDR-TB.

Received: December 12, 2018; 
Accepted: March 22, 2019

REFERENCES